CTLA 4 News and Research

RSS

Immunotherapy Response in Advanced Melanoma: Effect of Previous Treatments

According to a study conducted by UCLA, patients with advanced melanoma responded differently to PD-1 checkpoint blockade immunotherapy depending on a variety of variables, including whether or not they had previously received CTLA-4 blockade, another type of immunotherapy.

11 Apr 2023

Neoadjuvant dual immunotherapy and chemotherapy improve outcomes in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

20 Mar 2023

Pioneering gene editing approach could lead to new treatments for CTLA-4 insufficiency

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

From University College London 27 Oct 2022

New strategy to improve the therapeutic efficacy of liver cancer immunotherapy

In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.

8 Dec 2021

New technology efficiently delivers immune checkpoint inhibitors for treating brain tumors

Multi-institutional researchers have succeeded in efficiently delivering an immune checkpoint inhibitor (ICI) into the mouse brain, confirming its high efficacy and specificity in treating orthotopically transplanted mice with glioblastoma (GBM). The research was published in Nature Biomedical Engineering.

12 Oct 2021

New molecule can effectively deplete cancer-protecting cells inside tumors

A new study has discovered a two-arm molecule that can effectively deplete cancer-protecting cells within tumors.

16 Aug 2021

Study identifies how CTLA-4 blockade can disable suppressive immune cells to aid tumor destruction

A Ludwig Cancer Research study has identified a novel mechanism by which a type of cancer immunotherapy known as CTLA-4 blockade can disable suppressive immune cells to aid the destruction of certain tumors.

18 Feb 2021

Study suggests a way to improve immunotherapy by altering immune cells’ access to sugar

Cancer cells and immune cells share something in common: They both love sugar. Sugar is an important nutrient. All cells use sugar as a vital source of energy and building blocks. For immune cells, gobbling up sugar is a good thing, since it means getting enough nutrients to grow and divide for stronger immune responses. But cancer cells use sugar for more nefarious ends.

17 Feb 2021

Researchers identify a vital protein needed to regulate anti-tumor immune response

Scientists from The University of Texas MD Anderson Cancer Center have identified a protein known as NF-kappa B-inducing kinase (NIK).

5 Jan 2021

Study unravels how immunotherapy is 'uniquely suppressed' by liver cancers

Though cancer immunotherapy has become a promising standard-of-care treatment--and in some cases, perhaps a cure--for a wide variety of different cancers, it doesn't work for everyone, and researchers have increasingly turned their attention to understanding why.

5 Oct 2020